Trial Profile
Long-Term, Open-Label, Multicenter, Extension Study of Bosentan in Patients With Pulmonary Hypertension Associated With Sickle Cell Disease Completing a Double-Blind ASSET Study (AC-052-368 or AC 052-369) [EXTENSION OF 700243209 AND 700243212]
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 15 Apr 2014
Price :
$35
*
At a glance
- Drugs Bosentan (Primary)
- Indications Pulmonary hypertension
- Focus Registrational; Therapeutic Use
- Acronyms ASSET 3
- Sponsors Actelion Pharmaceuticals
- 15 Apr 2014 New trial record
- 11 Feb 2010
- 21 Sep 2008